Clinical Rheumatology

, Volume 33, Issue 7, pp 969–974

Diagnostic validity of colchicine in patients with Familial Mediterranean fever

  • Fatih Ozaltin
  • Yelda Bilginer
  • Bora Gülhan
  • Inci Bajin
  • Ozlem Erdogan
  • Mutlu Hayran
  • Engin Yılmaz
  • Seza Ozen
Original Article


Although response to colchicine has been proposed as one of the diagnostic criteria in patients with Familial Mediterranean fever (FMF), the validity of this response has not been validated. The aim of this study was to assess the efficacy of the response to colchicine and to evaluate the extent of the effect of placebo. A double-blind randomized placebo-controlled trial with a cross-over design was conducted. The frequency of FMF attacks, the disease score, physical examination, and acute phase reactants were assessed at 0, 3, and 6 months. Blood samples were collected for complete blood count (CBC), erythrocyte sedimentation rate (ESR), levels of serum C-reactive protein (CRP) and serum amyloid A (SAA), and MEFV mutation analysis in 79 patients with a preliminary diagnosis of FMF. Patients were randomly allocated to receive either drug A or drug B in a double-blind fashion. The designated drug was switched at 3 months. Patients taking colchicine had less frequent FMF attacks (median 0) and lower FMF disease score (median 0) when compared to those on placebo (median 1 and 3, respectively) (p = 0.002 and p = 0.007, respectively). In genetically confirmed FMF patients, median attack number and median disease score was 0 under colchicine treatment, whereas these parameters were significantly higher in the placebo group (median 2 and 8, respectively) (p = 0.007 and p = 0.02, respectively) suggesting that colchicine is more effective than placebo in reducing attacks and disease score. Positive and negative predictive values were 70.2 and 37.5 %, respectively. During the placebo period, patients had less FMF attacks when compared to that of the pre-study period (median 2 vs 6, respectively) (p < 0.001). The high false positive rate raises concerns for considering the colchicine response test as diagnostic for FMF. The role of placebo on the attacks of periodic fever syndromes needs to be further investigated.


Colchicine Diagnosis Familial Mediterranean fever Placebo 


  1. 1.
    Park H, Bourla AB, Kastner DL, Colbert RA, Siegel RM (2012) Lighting the fires within: the cell biology of autoinflammatory diseases. Nat Rev Immunol 12:570–580PubMedCrossRefGoogle Scholar
  2. 2.
    Samuels J, Ozen S (2006) Familial Mediterranean fever and the other autoinflammatory syndromes: evaluation of the patient with recurrent fever. Curr Opin Rheumatol 18:108–117PubMedCrossRefGoogle Scholar
  3. 3.
    Lidar M, Livneh A (2007) Familial Mediterranean fever: clinical, molecular and management advancements. Neth J Med 65:318–324PubMedGoogle Scholar
  4. 4.
    Hoffman HM (2009) Therapy of autoinflammatory syndromes. Allergy Clin Immunol 124:1129–1138CrossRefGoogle Scholar
  5. 5.
    Duzova A, Bakkaloglu A, Besbas N et al (2003) Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol 21:509–514PubMedGoogle Scholar
  6. 6.
    Yılmaz E, Ozen S, Balci B et al (2001) Mutation frequency of Familial Mediterranean fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet 9:553–555PubMedCrossRefGoogle Scholar
  7. 7.
    Livneh A, Langevitz P, Zemer D et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40:1879–1885PubMedCrossRefGoogle Scholar
  8. 8.
    Yalçinkaya F, Ozen S, Ozçakar ZB et al (2009) A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford) 48:395–398CrossRefGoogle Scholar
  9. 9.
    Tudor G, Koch GG (1994) Review of nonparametric methods for the analysis of crossover studies. Stat Methods Med Res 3:345–381PubMedCrossRefGoogle Scholar
  10. 10.
    Henderson C, Goldbach-Mansky R (2010) Monogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis. Curr Opin Rheumatol 22:567–578PubMedCentralPubMedGoogle Scholar
  11. 11.
    Aksentijevich I, Torosyan Y, Samuels J et al (1999) Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. Am J Hum Genet 64:949–962PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Stoffman N, Magal N, Shohat T et al (2000) Higher than expected carrier rates for familial Mediterranean fever in various Jewish ethnic groups. Eur J Hum Genet 8:307–310PubMedCrossRefGoogle Scholar
  13. 13.
    Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW (1974) Colchicine therapy for Familial Mediterranean fever. A double-blind trial. N Engl J Med 291:934–937PubMedCrossRefGoogle Scholar
  14. 14.
    Beecher HK (1955) The powerful placebo. J Am Med Assoc 159:1602–1606PubMedCrossRefGoogle Scholar
  15. 15.
    Hróbjartsson A, Gøtzsche PC (2004) Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J Intern Med 256:91–100PubMedCrossRefGoogle Scholar
  16. 16.
    Hróbjartsson A, Gøtzsche PC (2004) Placebo treatment versus no treatment. Cochrane Database Syst Rev (3):CD003974Google Scholar
  17. 17.
    Hróbjartsson A, Gøtzsche PC (2010) Placebo interventions for all clinical conditions. Cochrane Database Syst Rev (1):CD003974Google Scholar
  18. 18.
    Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB et al (2009) Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360:2416–2425PubMedCrossRefGoogle Scholar
  19. 19.
    Ben-Zvi I, Livneh A (2011) Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol 7:105–112PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2014

Authors and Affiliations

  • Fatih Ozaltin
    • 1
  • Yelda Bilginer
    • 1
  • Bora Gülhan
    • 1
  • Inci Bajin
    • 1
  • Ozlem Erdogan
    • 2
  • Mutlu Hayran
    • 3
  • Engin Yılmaz
    • 4
  • Seza Ozen
    • 1
  1. 1.Departments of Pediatric Nephrology and RheumatologyHacettepe University Faculty of MedicineAnkaraTurkey
  2. 2.Sami Ulus Children’s HospitalAnkaraTurkey
  3. 3.Department of Preventive OncologyHacettepe University Faculty of MedicineAnkaraTurkey
  4. 4.Department of Medical BiologyHacettepe University Faculty of MedicineAnkaraTurkey

Personalised recommendations